EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieVergleichsstudie

The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study

Paul Lorigan, Theresa Michelle Medina, Marta Nyakas, Annemie Rutten, Lynn G Feun, Charles Lance Cowey, Miranda Payne, Israr Hussain, Timothy Kuzel, Steven O'Day, Amna Sheri, Philip Adam Friedlander und 6 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2025.116162 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Paul Lorigan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Sciences, University of Manchester and Christie Hospital NHS Foundation Trust, Manchester, United Kingdom. Electronic address: pau…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cancer Vaccines, Ipilimumab, Melanoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCancer VaccinesIpilimumabMelanomaNivolumabSkin NeoplasmsTelomeraseAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedImmune Checkpoint InhibitorsProgression-Free Survival

Stichwörter der Autor:innen

ImmunotherapyIpilimumab and nivolumabMelanomaUV1 peptide vaccine

Substanzen

Cancer VaccinesImmune Checkpoint InhibitorsIpilimumabNivolumabTelomerase

Autor:innen und Institutionen

  • Division of Cancer Sciences, University of Manchester and Christie Hospital NHS Foundation Trust, Manchester, United Kingdom. Electronic address: paul.lorigan@nhs.net.
  • University of Colorado Comprehensive Cancer Center, Aurora, CO, United States.
  • Oslo University Hospital, Oslo, Norway.
  • AZ Sint-Augustinus (Belgium), Antwerpen, Belgium.
  • Sylvester Comprehensive Cancer Center, Miami, FL, United States.
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, United States.

Zitieren

APA

Lorigan, P., Medina, T. M., Nyakas, M., Rutten, A., Feun, L. G., Cowey, C. L., Payne, M., Hussain, I., Kuzel, T., O'Day, S., Sheri, A., Friedlander, P. A., Kumar, S., Bergersen, V. S., Foss, Ø., Ellingsen, E. B., Bjørheim, J., & Bechter, O. E. (2026). The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116162

Vancouver

Lorigan P, Medina TM, Nyakas M, Rutten A, Feun LG, Cowey CL, et al. The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2025.116162

BibTeX
@article{Lorigan2026,
  author = {Lorigan, Paul and Medina, Theresa Michelle and Nyakas, Marta and Rutten, Annemie and Feun, Lynn G and Cowey, Charles Lance and Payne, Miranda and Hussain, Israr and Kuzel, Timothy and O'Day, Steven and Sheri, Amna and Friedlander, Philip Adam and Kumar, Satish and Bergersen, Vanja Sue and Foss, Øivind and Ellingsen, Espen Basmo and Bjørheim, Jens and Bechter, Oliver Edgar},
  title = {The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2025.116162}
}
Kostenlos starten →